Ferroptosis, a recently recognized form of regulated cell death (RCD) characterized by iron-dependent lipid peroxide accumulation, has emerged as a noteworthy regulator in various bone-related diseases, including osteoporosis (OP), osteoarthritis (OA), and osteosarcoma (OS). OS primarily afflicts the elderly, rendering them susceptible to fractures due to increased bone fragility. OA represents the most prevalent arthritis in the world, often observed in the aging population. OS predominantly manifests during adolescence, exhibiting an aggressive nature and bearing a significantly unfavorable prognosis. In this review article, we present an overview of the characteristics and mechanism of ferroptosis and its involvement in bone-related diseases, with a particular focus on OP, OA, and OS. Furthermore, we summarize chemical compounds or biological factors that impact bone-related diseases by regulating ferroptosis. Through an in-depth exploration of ferroptosis based on current research findings, this review provides promising insights for potential therapeutic approaches to effectively manage and mitigate the impact of these bone-related pathological conditions.
Amyotrophic lateral sclerosis (ALS), commonly known as motor neuron disease, is a neurodegenerative disorder characterized by the progressive degeneration of both upper and lower motor neurons. This pathological process results in muscle weakness and can culminate in paralysis. To date, the precise etiology of ALS remains unclear. However, a burgeoning body of research indicates that axonal dysfunction is a pivotal element in the pathogenesis of ALS and significantly influences the progression of disease. Dysfunction of axons in ALS can result in impediments to nerve impulse transmission, leading to motor impairment, muscle atrophy, and other associated complications that severely compromise patients’ quality of life and survival prognosis. In this review, we concentrate on several key areas: the ultrastructure of axons, the mechanisms of axonal degeneration in ALS, the impact of impaired axonal transport on disease progression in ALS, and the potential for axonal regeneration within the central nervous system (CNS). Our objective is to achieve a more holistic and profound understanding of the multifaceted role that axons play in ALS, thereby offering a more intricate and refined perspective on targeted axonal therapeutic interventions.
Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disorder characterized by progressive loss of motor neurons (MNs). N6 -methyladenosine (m 6 A) is the most abundant mRNA modification, yet its role in ALS MNs degeneration remains poorly understood. In this study we observed a significant decrease in global m 6 A levels in the spinal cords of hSOD1 G93A transgenic ALS mouse model and hSOD1 G93A NSC34 cells, accompanied by reduced expression of the methyltransferase METTL3. Knocking down Mettl3 in the ALS MN model further impaired neurite outgrowth and acetylcholine release in an m 6 A-dependent manner. AAV-mediated Mettl3 overexpression attenuated MN loss, improved motor ability and extended survival in ALS mice. Integrated analysis based on m 6 A-methylome and transcriptome identified Fzd3 , a WNT signaling pathway receptor gene, as a key m 6 A-modified target. Mechanistically, METTL3 promotes the expression of FZD3 by enhancing the stability of its mRNA through IGF2BP3. Knockdown of Fzd3 abolished the protective effects of METTL3 on neurite outgrowth and acetylcholine release in ALS MNs. Collectively, our research reveals that METTL3-mediated m 6 A modification on Fzd3 mRNA plays a critical role in ALS pathogenesis and highlights METTL3 as a promising therapeutic target for ALS.
Amyotrophic lateral sclerosis (ALS) is a progressive and fatal neurodegenerative disease characterized by the selective degeneration of upper and lower motor neurons (MNs). Although the specific pathogenesis of ALS is not yet fully understood, there is increasing evidence that abnormal energy metabolism plays a key role in the onset and progression of the disease. Lactate has traditionally been considered a metabolic by-product of glycolysis and has received increasing attention in recent years. Research has shown that lactate is not only an important energy substrate but also a signaling molecule that regulates a variety of physiological processes, including neuron-glia metabolic coupling, neuroprotection and inflammatory responses. In ALS, abnormalities in lactate metabolism, dysfunction of the lactate shuttle, and dysregulation of lactate-related signaling pathways may jointly lead to neuronal energy deficits and increased neuroinflammation, thereby promoting MN degeneration. This review summarizes the latest advances in lactate metabolism and lactate-mediated signaling in ALS, with particular emphasis on their roles in neuronal energy regulation, neuroprotection and inflammatory regulation. In addition, we also discuss potential therapeutic strategies for lactate metabolism and its related pathways, aiming to provide new insights into the pathogenesis of ALS and the development of treatment methods for lactate-related metabolism.
Skeletal muscle-intrinsic defects are increasingly recognized as critical contributors to the pathogenesis of amyotrophic lateral sclerosis (ALS), yet the underlying molecular mechanisms remain poorly understood. N6 -methyladenosine (m 6 A) is the most abundant post-transcriptional RNA modification in mammalian mRNAs that plays important regulatory roles in diverse physiological and pathological processes, however its role in ALS-associated skeletal muscle atrophy remains unknown. Here we found that global m 6 A methylation and the expression of its methyltransferase METTL3 are reduced in the skeletal muscle of hSOD1 G93A transgenic ALS mice. Multi-omics analyses reveal that m 6 A dysregulation is closely associated with impaired triglyceride metabolism. Functionally, METTL3 promotes triglyceride accumulation in ALS skeletal muscle in an m 6 A-dependent manner; overexpression of METTL3 in ALS myotubes improves energy supply and alleviates muscle atrophy by promoting triglyceride accumulation. In vivo overexpression of Mettl3 in skeletal muscle attenuates muscle atrophy, improves motor performance, and prolongs survival of ALS mice. Mechanistically, we identify the fatty acid activation enzyme ACSL1 as a key downstream effector of METTL3-mediated regulation of triglyceride metabolism. METTL3-mediated m 6 A modification promotes the expression of Acsl1 by enhancing its mRNA stability. Further investigation revealed that the regulatory effect of m 6 A on Acsl1 expression depends on the m 6 A reader protein IGF2BP2. Collectively, our findings establish m 6 A modification as a critical regulator of skeletal muscle atrophy in ALS by maintaining triglyceride metabolic homeostasis, highlighting a promising therapeutic target for ALS.